Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2016-01-14 Director's Dealing
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2016-01-14 English
FORM 3 SUBMISSION
Director's Dealing
2016-01-14 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common stock, including details about the number of shares issued, pricing, and proceeds. It also references exhibits such as the underwriting agreement and legal opinion. This is a clear update on a capital raising event, specifically a financing transaction. The document is not a full financial report but an announcement of a financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2016-01-13 English
FILED PURSUANT TO RULE 424(B)(5)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering. It is not an annual report, earnings release, management discussion, or any other report type. The presence of underwriting details, offering price, and share numbers confirms it is a Capital/Financing Update filing.
2016-01-08 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) related to a preliminary prospectus for a common stock offering by Ardelyx, Inc. It details the number of shares offered, pricing, net proceeds, underwriters, and other offering-related information. This type of document is a capital markets communication about fundraising and securities issuance. It is not a full financial report, earnings release, or regulatory filing about financial results. It is specifically related to capital raising activities and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4577 characters, which is sufficient to contain substantive offering details rather than just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2016-01-08 English
FORM 4
Director's Dealing
2016-01-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.